Transfusional Iron Overload and Iron Chelation Therapy in Thalassemia Major and Sickle Cell Disease - 25/07/14
Résumé |
Iron overload is an inevitable consequence of blood transfusions and is often accompanied by increased iron absorption from the gut. Chelation therapy is necessary to prevent the consequences of hemosiderosis. Three chelators, deferoxamine, deferiprone, and deferasirox, are presently available and a fourth is undergoing clinical trials. The efficacy of all 3 available chelators has been demonstrated. Also, many studies have shown the efficacy of the combination of deferoxamine plus deferiprone as an intensive treatment of severe iron overload. Alternating chelators can reduce adverse effects and improve compliance. Adherence to therapy is crucial for good results.
Le texte complet de cet article est disponible en PDF.Keywords : Thalassemia major, Sickle cell disease, Iron overload, Iron chelation, Deferoxamine, Deferiprone, Deferasirox
Plan
| Disclosure: C. Borgna-Pignatti has received speaker’s honoraria from Apopharma and Novartis. M. Marsella reports no conflicts of interest. |
Vol 28 - N° 4
P. 703-727 - août 2014 Retour au numéro
Article précédent
- The Pathophysiology of Transfusional Iron Overload
- John B. Porter, Maciej Garbowski
- Diagnosis and Management of Iron Deficiency Anemia
- Jacquelyn M. Powers, George R. Buchanan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?